The reform of EU pharmaceutical legislation represents one of the most significant transformations of the regulatory framework for medicinal products in recent decades.
During this session, organized by Navarra Health Cluster, Asphalion expert Carmen Ortega Quintanilla explored the main objectives and key developments introduced by the new Regulation and Directive, as well as their implications for the pharmaceutical sector.
Understanding these changes is essential for anticipating regulatory challenges and preparing for the evolving European pharmaceutical landscape.
Would you like to explore the regulatory challenges facing the pharmaceutical sector further? Join us for our next webinar on 3 December: “EU Pharma Reform: What Companies Need to Know Now.”
The reform of EU pharmaceutical legislation will reshape the regulatory framework for medicines in Europe. Discover the key changes affecting regulatory protection and incentives, patient access, the development of orphan and paediatric medicines, security of supply, antimicrobial resistance, and sustainability.
More details and registration: https://bit.ly/47QXjJq
Need help in Regulatory? Contact us: [email protected]
